Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurosurg Pediatr ; 3(5): 386-91, 2009 May.
Article in English | MEDLINE | ID: mdl-19409017

ABSTRACT

Intracranial osteolipomas and chondromas are rare benign tumors. Forty-five chondromas, mostly supratentorial, have been reported in the literature since 1981, with origins most commonly in the sellar regions. Twenty-one osteolipomas have been described to date, usually located near the tuber cinereum or the corpus callosum. The authors present a case of an osteochondrolipoma arising from the tentorium diagnosed in a pediatric patient at the age of 9 years. The case and treatment are discussed, and a review of the literature is provided.


Subject(s)
Infratentorial Neoplasms/diagnosis , Lipoma/diagnosis , Ossification, Heterotopic/pathology , Osteochondroma/diagnosis , Tuber Cinereum/pathology , Child , Humans , Infratentorial Neoplasms/pathology , Infratentorial Neoplasms/surgery , Lipoma/pathology , Lipoma/surgery , Magnetic Resonance Imaging , Male , Ossification, Heterotopic/physiopathology , Ossification, Heterotopic/surgery , Osteochondroma/pathology , Osteochondroma/surgery , Tuber Cinereum/physiopathology , Tuber Cinereum/surgery
2.
Am J Infect Control ; 36(1): 54-8, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18241737

ABSTRACT

Pediatric oncologists from Germany systematically reviewed the literature, considering the use of urokinase in pediatric oncology patients published since 1998 and came to the following conclusions. The use of urokinase to prevent central venous access device (CVAD)-related infections in pediatric cancer patients represents an evidence-based approach, at least in external, tunneled catheters (eg, Hickman, Broviac). The effectiveness of urokinase prophylaxis in decreasing infections and thrombotic events is probably related not only to the concentration and timing of the urokinase intervention but also to the type of CVAD, and perhaps to the intensity of the concomitant chemotherapy program. Urokinase can safely and effectively be used on CVADs with malfunctioning or intraluminal occlusion in a dose of 5000 IU/mL or as salvage 3-hour infusion with 1000 IU/kg/hour. Hitherto, adjuvant treatment with urokinase in the management of CVADs with intraluminal infection still relies on case reports and small case series. In this field, a randomized controlled study is necessary.


Subject(s)
Blood Coagulation/drug effects , Catheterization, Central Venous/methods , Chemoprevention/statistics & numerical data , Cross Infection/prevention & control , Neoplasms/complications , Urokinase-Type Plasminogen Activator/pharmacology , Catheters, Indwelling/microbiology , Chemoprevention/methods , Child , Germany , Humans , Neoplasms/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...